China Meheco(SH:600056) 智通财经网·2025-08-13 08:13Core Viewpoint - China Medical (600056.SH) announced that its wholly-owned subsidiary Tianfang Pharmaceutical Co., Ltd. received approval from the National Medical Products Administration for the market application of fumaric acid volnorasone, which is primarily used for treating gastroesophageal reflux disease and eradicating Helicobacter pylori when used in conjunction with appropriate antibiotics [1] Group 1 - Tianfang Pharmaceutical's approval for fumaric acid volnorasone indicates that the raw material meets domestic drug registration requirements and has been approved for use in domestic formulations [1] - The approval of this raw material will further solidify the company's integrated development strategy of raw materials and formulations [1] - This development will expand the company's product range and accumulate valuable experience for future raw material drug applications [1]